Project Grant R01DC024211
- The National Institute on Deafness and Other Communication Disorders (NIDCD), part of the National Institutes of Health, awarded The Washington University $557,999 on September 1, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). The award funds investigation of how inner hair cells in the cochlea encode sound frequency and intensity across a wide dynamic range. The research employs in vivo two-photon cochlear imaging integrated with single-cell...
- The National Cancer Institute awarded The Medical University of South Carolina $128,003 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the neural and developmental mechanisms of cisplatin-induced ototoxicity. The research addresses cisplatin-related hearing loss in cancer survivors by examining cellular damage beyond the well-characterized loss of outer hair cells. The project hypothesizes that cisplatin disrupts chromatin accessibility and gene...
- The National Institute on Deafness and Other Communication Disorders awarded The Washington University $464,646 under Project Grant R01DC024001 on July 15, 2026, to investigate cortical mechanisms underlying hearing deficits in noisy environments following noise-induced hearing loss. The research employs longitudinal in vivo two-photon calcium imaging in awake mice to characterize responses of primary auditory cortex neurons—including glutamatergic principal neurons and inhibitory interneurons...
- The National Institute on Deafness and Other Communication Disorders awarded the University of Washington $490,487 on February 13, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to study spatial patterning in the zebrafish inner ear and its relevance to vestibular dysfunction in humans. The project investigates how hair cells in vestibular organs establish distinct central and peripheral regions with conserved functional and molecular identities...
- The National Institute on Deafness and Other Communication Disorders awarded The University of Chicago $451,000 on August 24, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to develop a native biochemical preparation of the mechanotransduction complex (METC) from cnidarian nematocytes as a model of vertebrate hair-cell function. The award funds research into the structural dynamics and functional mechanisms of the METC, the cellular machinery...
- The National Institute on Deafness and Other Communication Disorders awarded The Johns Hopkins University $687,094 on February 23, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate mechanisms of hair cell mechanotransduction and the protein defects that cause deafness. The recipient will use genetically modified organisms combined with biochemical, cell biological, and electrophysiological methods to study how mechanical force regulates...
- The National Institute on Deafness and Other Communication Disorders awarded the University of Miami $484,738 on May 1, 2026, for project grant R01DC022861 under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). The award funds development of a human pluripotent stem cell system to study inner ear development and disease. The recipient will engineer a microphysiological system featuring a microfluidic chip to establish precise morphogen concentration...
- The National Institute on Deafness and Other Communication Disorders awarded the University of Pittsburgh $659,250 on May 7, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). The award funds research into critical proteins regulating mechanotransduction channel trafficking and localization in cochlear hair cells, which are essential for converting sound waves into electrical signals and maintaining auditory function. The research addresses how...
- Federal Grant Award Summary Massachusetts Eye and Ear Infirmary received a $473,749 Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), effective September 11, 2025, with completion targeted for August 31, 2027. The award funds in silico screening and in vivo evaluation of FDA-approved drugs to prevent noise-induced hearing loss (NIHL) by targeting the...
- The National Institute on Deafness and Other Communication Disorders awarded Oregon Health & Science University $645,488 on July 27, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to characterize how the auditory cortex processes speech and natural sounds in noisy, dynamic acoustic environments. The research addresses the clinical problem that listeners with hearing loss struggle to understand speech in complex noise despite hearing aids and...
The National Institute on Deafness and Other Communication Disorders awarded The Washington University $647,082 on August 24, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate mechanisms of hair cell vulnerability following sublethal cisplatin exposure. The research examines how cisplatin, a widely used cancer treatment, causes permanent hearing loss in patients years after treatment ends and sensitizes the cochlea to subsequent noise trauma. The work combines mechanistic studies in zebrafish lateral line with a mouse model that mirrors clinical cisplatin treatment regimens followed by environmental noise challenge. Studies will assess how cisplatin-induced disruption of mitochondrial homeostasis and function in hair cells—which may appear structurally intact initially—drives increased cochlear vulnerability without causing immediate hearing loss. The objectives include defining how mitochondrial dysregulation creates hair cell vulnerability and testing interventions that promote cochlear repair following cisplatin treatment. Understanding these mechanisms is essential for developing therapies that protect hearing in cancer survivors without compromising cisplatin's anti-cancer properties. The award period runs through July 31, 2031, with place of performance at St. Louis, Missouri. The Washington University's Office of Sponsored Research Services serves as the recipient organization.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $647.1k | 8/26/26 |